ConductScience.org, home

Trial · NCT03435640

Adverse events3,058

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEvents
otherFatigueGeneral disordersCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)23
otherFatigueGeneral disordersCohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)33
otherFatigueGeneral disordersCohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)24
otherFatigueGeneral disordersCohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)13
otherFatigueGeneral disordersCohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)34
otherFatigueGeneral disordersCohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)24
otherFatigueGeneral disordersCohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)34
otherFatigueGeneral disordersCohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)13
otherFatigueGeneral disordersCohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)48
otherFatigueGeneral disordersCohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)814
otherFatigueGeneral disordersCohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab614
otherInfluenza like illnessGeneral disordersCohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered)23
otherInfluenza like illnessGeneral disordersCohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered)03
otherInfluenza like illnessGeneral disordersCohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day)24
otherInfluenza like illnessGeneral disordersCohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day)13
otherInfluenza like illnessGeneral disordersCohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day)24
otherInfluenza like illnessGeneral disordersCohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day)24
otherInfluenza like illnessGeneral disordersCohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day)04
otherInfluenza like illnessGeneral disordersCohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day)13
otherInfluenza like illnessGeneral disordersCohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day)58

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03435640/events